Investor Toolkit

Press Release

Company exceeds full year 2016 guidance, posts revenue of $301.9
million, net income of $26.8 million and Adjusted EBITDA of $78.3 million

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 21, 2017--
Lantheus
Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus
Medical Imaging, Inc. (“LMI”), a global leader in the development,
manufacture and commercialization of innovative diagnostic imaging
agents and products, today reported financial results for its fourth
quarter and full year ended December 31, 2016.

The Company’s worldwide revenues for the fourth quarter of 2016 totaled
$74.4 million, compared to $71.2 million for the fourth quarter of 2015.
For the full year 2016, worldwide revenues totaled $301.9 million,
compared to $293.5 in 2015, exceeding 2016 guidance of $296 million to
$299 million. Revenue results were driven by growth in sales of DEFINITY®
and TechneLite®, partially offset by price concessions for
Xenon as part of the Company’s nuclear products contracting strategy as
well as the divestiture of the Company’s Canadian and Australian
radiopharmacy businesses.

Net income for the fourth quarter of 2016 totaled $4.9 million or $0.13
per diluted share, compared to $3.9 million or $0.13 per diluted share
for the fourth quarter of 2015. Full year 2016 net income totaled $26.8
million, compared to a net loss of $14.7 million in 2015. The full year
$41.5 million improvement is primarily attributable to operational
improvements, decreased interest expense and one-time activities in 2015
associated with the Company’s initial public offering and debt
refinancing.

The Company’s fourth quarter 2016 Adjusted EBITDA (as defined below in
the GAAP to non-GAAP reconciliation) was $19.8 million, or 26.7% of
revenues, compared to $18.3 million, or 25.7% of revenues, in the fourth
quarter of 2015. Full year 2016 Adjusted EBITDA was $78.3 million, or
25.9% of revenues, compared to $76.3 million, or 26.0% of revenues, for
2015, exceeding 2016 guidance of $73 million to $75 million. Higher
Adjusted EBITDA was attributable to the strong performance of higher
margin products in the U.S. and the Company’s shift to a distribution
model in Canada and Australia, partially offset by the margin impact of
price concessions attributed to the Company’s nuclear products
contracting strategy and incremental sales and marketing expenses
attributable to the growth of DEFINITY sales.

Mary Anne Heino, President and CEO, commented, “2016 was a successful
year for the Company on a number of levels as we exceeded both revenue
and Adjusted EBITDA guidance, delivering significant value to
shareholders. Our strong results reflect 18.1% revenue growth of
DEFINITY worldwide, execution of our nuclear products contracting
strategy, and a consistent focus on optimizing our capital structure,
including $75 million of reduction in our outstanding debt. We enter
2017 poised to drive continued growth while remaining focused on
building our portfolio and strengthening the long-term financial results
of the Company.”

Outlook

The Company anticipates worldwide revenues for full year 2017 of
approximately $312 million to $317 million, compared to $301.9 million
in 2016. For the first quarter of 2017, the Company expects worldwide
revenues in the range of $77 million to $80 million.

The Company anticipates full year 2017 Adjusted EBITDA, as described in
the GAAP to non-GAAP reconciliation provided later in this release, of
$79 million to $82 million, representing 24.9% to 26.3% of anticipated
worldwide revenues. For the first quarter of 2017, the Company expects
Adjusted EBITDA in the range of $18 million to $20 million.

The Company’s guidance for worldwide revenues and Adjusted EBITDA are
forward-looking statements. They are subject to various risks and
uncertainties that could cause the Company’s actual results to differ
materially from guidance. Forward-looking statements are not predictions
of the Company’s actual performance. See the cautionary information
about forward-looking statements in the “Safe-Harbor Statement” section
of this press release.

Internet Posting of Information

The Company routinely posts information that may be important to
investors in the “Investors” section of its website at www.lantheus.com.
The Company encourages investors and potential investors to consult its
website regularly for important information about the Company.

Conference Call and Webcast

As previously announced, the Company will host a conference call
starting at 4:30 p.m. Eastern Time today. To access the live conference
call via telephone, please dial 1-866-498-8390 (U.S. callers) or
1-678-509-7599 (international callers) and provide passcode 65019185. A
live audio webcast of the call also will be available in the Investors
section of the Company’s website at www.lantheus.com.

A replay of the audio webcast will be available in the Investors section
of our website at www.lantheus.com
approximately two hours after completion of the call and will be
archived for 30 days.

The conference call will include a discussion of non-GAAP financial
measures. Reference is made to the most directly comparable GAAP
financial measures, the reconciliation of the differences between the
two financial measures, and the other information included in this press
release, our Form 8-K filed with the SEC today, or otherwise available
in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the
cautionary information about forward-looking statements in the
safe-harbor section of this press release.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, a global leader in
the development, manufacture and commercialization of innovative
diagnostic imaging agents and products. LMI provides a broad portfolio
of products, which are primarily used for the diagnosis of
cardiovascular diseases. LMI’s key products include the echocardiography
contrast agent DEFINITY® Vial for (Perflutren Lipid
Microsphere) Injectable Suspension; TechneLite® (Technetium
Tc99m Generator), a technetium-based generator that provides the
essential medical isotope used in nuclear medicine procedures; and Xenon
(Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to
evaluate pulmonary function and for imaging the lungs. The Company is
headquartered in North Billerica, Massachusetts with offices in Puerto
Rico and Canada. For more information, visit www.lantheus.com.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as revenues excluding
the impact of foreign currency; adjusted operating income; adjusted net
income; Adjusted EBITDA; adjusted net income per share - diluted; and
free cash flow. The Company’s management believes that the presentation
of these measures provides useful information to investors. These
measures may assist investors in evaluating the Company’s operations,
period over period. The measures may exclude such items which may be
highly variable, difficult to predict and of a size that could have
substantial impact on the Company’s reported results of operations for a
period. Management uses these and other non-GAAP measures internally for
evaluation of the performance of the business, including the allocation
of resources and the evaluation of results relative to employee
performance compensation targets. Investors should consider these
non-GAAP measures only as a supplement to, not as a substitute for or as
superior to, measures of financial performance prepared in accordance
with GAAP.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” as defined
under U.S. federal securities laws, including statements about our 2017
outlook.. Forward-looking statements may be identified by their use of
terms such as anticipate, believe, confident, could, estimate, expect,
intend, may, plan, predict, project, target, will and other similar
terms. Such forward-looking statements are subject to risks and
uncertainties that could cause actual results to materially differ from
those described in the forward- looking statements. Readers are
cautioned not to place undue reliance on the forward-looking statements
contained herein, which speak only as of the date hereof. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future developments
or otherwise, except as may be required by law. Risks and uncertainties
that could cause our actual results to materially differ from those
described in the forward-looking statements are discussed in our filings
with the Securities and Exchange Commission (including those described
in the Risk Factors section in our Annual Reports on Form 10-K and our
Quarterly Reports on Form 10-Q). This press release includes
forward-looking non-GAAP guidance for 2017 Adjusted EBITDA. No
reconciliation of this forward-looking non-GAAP guidance was included in
this press release because, due to the high variability and difficulty
in making accurate forecasts and projections of some of the excluded
information, together with some of the excluded information not being
ascertainable or accessible, the Company is unable to quantify certain
amounts that would be required to be included in the most directly
comparable GAAP financial measure without unreasonable efforts.

(a) Represents provision for income taxes, less tax indemnification
associated with BMS.(b) Represents legal fees and disbursements
incurred in connection with our business interruption claim associated
with the NRU reactor shutdown in 2009 to 2010.(c) Represents
non-cash losses incurred associated with the write-down of inventory and
write-off of long-lived assets.(d) The amounts consist of
severance and recruitment costs related to employees, executives and
directors.(e) Represents expenses paid on behalf of our former
sponsor’s secondary offering in 2016, annual sponsor monitoring fee and
related expenses and a $6.5 million payment for the termination of our
advisory services and monitoring agreement with our sponsor in 2015.(f)
Represents internal and external costs associated with establishing new
manufacturing sources for our commercial and clinical candidate products.